NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients